Edward L. Kaplan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Edward L. Kaplan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Dwight R. Johnson
Department of Pediatrics, University of Minnesota Medical School, Minneapolis, Minnesota, USA
3 shared publications- Anita Shet
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States
1 shared publication Dwight R Johnson
Department of Pediatrics, WHO Collaborating Center for Reference and Research on Streptococci, University of Minnesota Medical School, Minneapolis, MN, USA
1 shared publication- Dwight R. Johnson
Department of Pediatrics, World Health Organization Collaborating Center for Reference and Research on Streptococci, University of Minnesota Medical School, 420 Delaware Street SE, Minneapolis, MN 55455, USA
1 shared publication Giuseppe Cornaglia
Department of Pathology, University of Verona Medical School, Verona, Italy
1 shared publicationGursharan S. Chhatwal
Department of Microbial Pathogenesis; Helmholtz Centre for Infection Research, Braunschweig, Germany
1 shared publication
Latest Publications
- 5 November 2013
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 159 (9) , 638-639
Streptococcal Pharyngitis in Adults: Can It Be Efficiently and Effectively Managed by Remote Control?
- 5 November 2013
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 159 (9) , 638-639
Streptococcal Pharyngitis in Adults: Can It Be Efficiently and Effectively Managed by Remote Control?
- 22 January 2013
- Published by Springer Nature
- Vol. 368, 243-252
Clinical Management of the Most Common Group A β-Hemolytic Streptococcal Infections
Group A streptococcal (Streptococcus pyogenes) infections remain important causes of medical and public health morbidity and mortality even during the early twenty-first century. Although most often concentrated in socially/economically disadvantaged populations, the problems remain significant in both industrializing and industrialized countries. The many M/emm types of GAS contribute to herd immunity in populations and also affect the control of streptococcal infections in these populations. Although this bacterium remains among the most susceptible to most antibiotics, it is evident that antibiotics alone have not solved the group A streptococcal medical and public health problems, even in those places where access to medical care is readily available. It is likely that the current streptococcal problems will remain difficult to manage and will remain essentially unchanged until the broad implementation of a cost-effective group A streptococcal vaccine, likely some years in the future.
- 22 January 2013
- Published by Springer Nature
- Vol. 368, 243-252
Clinical Management of the Most Common Group A β-Hemolytic Streptococcal Infections
Group A streptococcal (Streptococcus pyogenes) infections remain important causes of medical and public health morbidity and mortality even during the early twenty-first century. Although most often concentrated in socially/economically disadvantaged populations, the problems remain significant in both industrializing and industrialized countries. The many M/emm types of GAS contribute to herd immunity in populations and also affect the control of streptococcal infections in these populations. Although this bacterium remains among the most susceptible to most antibiotics, it is evident that antibiotics alone have not solved the group A streptococcal medical and public health problems, even in those places where access to medical care is readily available. It is likely that the current streptococcal problems will remain difficult to manage and will remain essentially unchanged until the broad implementation of a cost-effective group A streptococcal vaccine, likely some years in the future.
- 18 August 2011
- Published by S. Karger AG
- Vol. 72, 129-131
Immunologic Impact of Tonsillopharyngitis Associated with Group A Streptococci
While very common clinically, group A streptococcal infections of the upper respiratory tract remain incompletely understood. Vital to clarifying these incompletely answered questions is the understanding of the immune responses associated with infection and the enigmatic 'carrier state'. An important aspect of this is understanding the differences between an immune response and a protective immune response. Several of these concerns are discussed.
- 18 August 2011
- Published by S. Karger AG
- Vol. 72, 129-131
Immunologic Impact of Tonsillopharyngitis Associated with Group A Streptococci
While very common clinically, group A streptococcal infections of the upper respiratory tract remain incompletely understood. Vital to clarifying these incompletely answered questions is the understanding of the immune responses associated with infection and the enigmatic 'carrier state'. An important aspect of this is understanding the differences between an immune response and a protective immune response. Several of these concerns are discussed.
- Open Access
- 15 February 2010
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 50 (4) , 481-490
The Human Immune Response to Streptococcal Extracellular Antigens: Clinical, Diagnostic, and Potential Pathogenetic Implications
Background. Determination of an immune response to group A Streptococcus (GAS) antigens, frequently anti–streptolysin O and anti–DNase B, is crucial
- 15 February 2010
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 50 (4) , 481-490
Open AccessThe Human Immune Response to Streptococcal Extracellular Antigens: Clinical, Diagnostic, and Potential Pathogenetic Implications
Background. Determination of an immune response to group A Streptococcus (GAS) antigens, frequently anti–streptolysin O and anti–DNase B, is crucial
- Open Access
- 1 May 2009
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 48 (9) , 1220-1222
Some Things Never Change!
Potential conflicts of interest. E.L.K.: no conflicts.
- 1 May 2009
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 48 (9) , 1220-1222
Open AccessSome Things Never Change!
Potential conflicts of interest. E.L.K.: no conflicts.
- 1 December 2007
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 26 (12) , 1110-1116
Unexpected Individual Clinical Site Variation in Eradication Rates of Group A Streptococci by Penicillin in Multisite Clinical Trials
Previously, we reported an unexpectedly large percentage of failures by penicillin to eradicate group A streptococci (GAS) from the upper respiratory tract. Because penicillin has been the recommended therapy for the treatment of GAS pharyngitis, our report prompted controversy. Data from clinical trials in which our laboratory has participated demonstrated marked variation in GAS eradication rates among clinical sites. The reasons for such variation have never been adequately examined. We performed statistical analyses of site variation in eradication rates to assess the potential effect on reported reduced penicillin efficacy. Penicillin GAS eradication rates were compared using data from 4 large multisite pharyngitis treatment trials (75 clinical sites; 1158 subjects). Variation in eradication rates among clinical sites was statistically evaluated [chi(2) tests and generalized estimating equation (GEE) regression models]. There was significant site-to-site variation in GAS eradication rates in each of the trials (range, 17-100%; P < 0.005) as well as between separate trials (mean range, 58-69%; P < 0.033). GEE modeling indicated that GAS eradication rates were significantly higher for clinical sites participating in more than one clinical trial. The statistically significant site-to-site variation in penicillin eradication rates was related to factors (dependencies) at individual sites. Such factors may affect assessment of therapeutic efficacy and indicate a necessity for considering clinical site variation before reporting pooled efficacy data from multiple sites; combined data may result in misleading clinical implications. This is the first report documenting significant variation resulting from individual clinical site-related factors and offers a possible explanation for reduced penicillin eradication.
- 1 December 2007
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 26 (12) , 1110-1116
Unexpected Individual Clinical Site Variation in Eradication Rates of Group A Streptococci by Penicillin in Multisite Clinical Trials
Previously, we reported an unexpectedly large percentage of failures by penicillin to eradicate group A streptococci (GAS) from the upper respiratory tract. Because penicillin has been the recommended therapy for the treatment of GAS pharyngitis, our report prompted controversy. Data from clinical trials in which our laboratory has participated demonstrated marked variation in GAS eradication rates among clinical sites. The reasons for such variation have never been adequately examined. We performed statistical analyses of site variation in eradication rates to assess the potential effect on reported reduced penicillin efficacy. Penicillin GAS eradication rates were compared using data from 4 large multisite pharyngitis treatment trials (75 clinical sites; 1158 subjects). Variation in eradication rates among clinical sites was statistically evaluated [chi(2) tests and generalized estimating equation (GEE) regression models]. There was significant site-to-site variation in GAS eradication rates in each of the trials (range, 17-100%; P < 0.005) as well as between separate trials (mean range, 58-69%; P < 0.033). GEE modeling indicated that GAS eradication rates were significantly higher for clinical sites participating in more than one clinical trial. The statistically significant site-to-site variation in penicillin eradication rates was related to factors (dependencies) at individual sites. Such factors may affect assessment of therapeutic efficacy and indicate a necessity for considering clinical site variation before reporting pooled efficacy data from multiple sites; combined data may result in misleading clinical implications. This is the first report documenting significant variation resulting from individual clinical site-related factors and offers a possible explanation for reduced penicillin eradication.
- Open Access
- 1 December 2006
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (11) , 1398-1406
Reduced Ability of Penicillin to Eradicate Ingested Group A Streptococci from Epithelial Cells: Clinical and Pathogenetic Implications
Background. Group A streptococci (Streptococcus pyogenes; GAS) invades human epithelial cell lines. Failure of penicillin to eradicate GAS from the throats of patients, especially those who are GAS “carriers,” has been increasingly reported. However, there has been no comprehensive evaluation of how effectively antibiotics that are used to treat GAS enter upper respiratory tract epithelial cells and kill internalized GAS. We examined the viability of ingested, intracellular GAS after epithelial cell exposure to antibiotics commonly recommended for therapy of GAS infections.
- 1 December 2006
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 43 (11) , 1398-1406
Open AccessReduced Ability of Penicillin to Eradicate Ingested Group A Streptococci from Epithelial Cells: Clinical and Pathogenetic Implications
Background. Group A streptococci (Streptococcus pyogenes; GAS) invades human epithelial cell lines. Failure of penicillin to eradicate GAS from the throats of patients, especially those who are GAS “carriers,” has been increasingly reported. However, there has been no comprehensive evaluation of how effectively antibiotics that are used to treat GAS enter upper respiratory tract epithelial cells and kill internalized GAS. We examined the viability of ingested, intracellular GAS after epithelial cell exposure to antibiotics commonly recommended for therapy of GAS infections.
- Open Access
- 1 September 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (5) , 609-611
Persistent Macrolide Resistance among Group A Streptococci: The Lack of Accomplishment after 4 Decades
After isolation of erythromycin from a culture of Streptomyces erythreus in 1952 and the soon-to-follow introduction of erythromycin to clinical practice, erythromycin resistance required Streptococcus pyogenes). A 1968 report in 1968 by Sanders et al. [1] about an erythromycin-resistant GAS (M type 12) isolate recovered from a patient's upper respiratory tract concluded with the admonition, “Therefore, determination of the in-vitro susceptibility of group A streptococci to these drugs appears advisable whenever their use is contemplated, and imperative when either the infection threatens life or there is an increased risk that late sequelae of such infections will develop.” Now, decades later, Richter et al. [2] similarly admonish physicians in their survey of macrolide resistance in the United States: “In vitro testing of S. pyogenes for macrolide susceptibility is warranted for patients who are allergic to β-lactams” (p. 606). Unfortunately, during this 37-year interval, there has been little change in the need to caution practitioners about the potential for macrolide resistance.
- 1 September 2005
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 41 (5) , 609-611
Open AccessPersistent Macrolide Resistance among Group A Streptococci: The Lack of Accomplishment after 4 Decades
After isolation of erythromycin from a culture of Streptomyces erythreus in 1952 and the soon-to-follow introduction of erythromycin to clinical practice, erythromycin resistance required Streptococcus pyogenes). A 1968 report in 1968 by Sanders et al. [1] about an erythromycin-resistant GAS (M type 12) isolate recovered from a patient's upper respiratory tract concluded with the admonition, “Therefore, determination of the in-vitro susceptibility of group A streptococci to these drugs appears advisable whenever their use is contemplated, and imperative when either the infection threatens life or there is an increased risk that late sequelae of such infections will develop.” Now, decades later, Richter et al. [2] similarly admonish physicians in their survey of macrolide resistance in the United States: “In vitro testing of S. pyogenes for macrolide susceptibility is warranted for patients who are allergic to β-lactams” (p. 606). Unfortunately, during this 37-year interval, there has been little change in the need to caution practitioners about the potential for macrolide resistance.
- Open Access
Pathogenesis of acute rheumatic fever and rheumatic heart disease: evasive after half a century of clinical, epidemiological, and laboratory investigation
Rheumatic fever and rheumatic heart disease continue to be a problem for medical and public health communities—the fact that penicillin has failed to eradicate this disease process is irrefutable proof of the need for more laboratory, epidemiological, and clinical research
Open AccessPathogenesis of acute rheumatic fever and rheumatic heart disease: evasive after half a century of clinical, epidemiological, and laboratory investigation
Rheumatic fever and rheumatic heart disease continue to be a problem for medical and public health communities—the fact that penicillin has failed to eradicate this disease process is irrefutable proof of the need for more laboratory, epidemiological, and clinical research
Rheumatic heart disease in rural Pakistan
In the developing countries of the world, rheumatic fever and rheumatic heart disease remain significant medical and public health problems
Rheumatic heart disease in rural Pakistan
In the developing countries of the world, rheumatic fever and rheumatic heart disease remain significant medical and public health problems